You are here

  • Home
  • Archive
  • Volume 21, Issue 1
  • Initiating antiretroviral therapy in HIV-infected patients with >500 CD4 cells/µL provides more benefit than delaying treatment

Article info

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
Initiating antiretroviral therapy in HIV-infected patients with >500 CD4 cells/µL provides more benefit than delaying treatment

Authors

  • George W Rutherford Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA; Department of Global Health Sciences, University of California, San Francisco, San Francisco, California, USA; PubMed articlesGoogle scholar articles
  • Andrew Anglemyer Department of Health, Human Services and Public Policy, California State University Monterey Bay, Seaside, California, USA PubMed articlesGoogle scholar articles
  1. Correspondence to : Professor George W Rutherford, Department of Global Health Sciences, University of California, San Francisco, Mission Hall, 550 16th Street, P.O. Box 1224, San Francisco, CA 94143-1224, USA; george.rutherford{at}ucsf.edu
View Full Text

Citation

Rutherford GW, Anglemyer A
Initiating antiretroviral therapy in HIV-infected patients with >500 CD4 cells/µL provides more benefit than delaying treatment
BMJ Evidence-Based Medicine 2016;21:26.

Publication history

  • First published December 11, 2015.
Online issue publication 
April 09, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/